Trends in net survival for patients with stomach cancer in Japan, 2000–14 (CONCORD-3)
- 20 March 2026
- journal article
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 56 (Supplement) , i25-i33
Abstract
Background: We estimated net survival trends for patients with stomach cancer registered in 16 regional population-based cancer registries in Japan that participated in the CONCORD-3 study. Methods: We included data on adults (15–99 years) diagnosed with stomach cancer between 2000 and 2014 and followed-up for their vital status until 31 December 2014. We grouped cancer patients into three anatomic groups (proximal, distal, and overlapping regions and stomach cancer, not otherwise specified) with the International Classification of Disease for Oncology, Third edition topography codes. We estimated 5-year net survival with the Pohar Perme estimator for three calendar periods (2000–2004, 2005–2009, 2010–2014), by age group (15–44, 45–54, 55–64, 65–74, and 75–99 years), anatomic group, and stage at diagnosis. All-ages survival estimates were age-standardized using the International Cancer Survival Standard weights. Results: Five-year net survival improved over time, from 50.5% in 2000–2004 to 57.6% and 60.3% in 2005–2009 and 2010–2014, respectively. Survival for patients with proximal stomach cancer improved from 49.7% in 2000–2004 to 53.5% 2005–2009 and plateaued to 53.1% in 2010–2014. Survival for distal stomach cancer increased from 64.8% in 2000–2004 to 67.6% and 68.2% in 2005–2009 and 2010–2014, respectively. In 2010–2014, 5-year net survival for patients with localized disease (94.8%) was much higher than survival for regional (53.7%) and distant (6.4%) disease. Conclusions: Five-year net survival for stomach cancer improved noticeably during 2000–2014. This improvement might be due to advances in systemic chemotherapy. Although survival in distal stomach cancer had improved, no such improvement was seen in proximal stomach cancer. Standardizing esophagogastric junction cancer treatment may improve its outcomes and contribute to better survival in proximal stomach cancer overall. Scientific evaluation of screening programs is also needed to enhance the efficacy of stomach cancer control initiatives in Japan.Keywords
Funding Information
- Japanese Ministry of Health, Labour and Welfare (Cancer Control-General 23EA1033)
This publication has 16 references indexed in Scilit:
- Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countriesThe Lancet, 2018
- Effectiveness of the Korean National Cancer Screening Program in Reducing Gastric Cancer MortalityGastroenterology, 2017
- The efficacy and safety of S-1-based regimens in the first-line treatment of advanced gastric cancer: a systematic review and meta-analysisGastric Cancer, 2016
- Comparison of advanced adenocarcinomas of esophagogastric junction and distal stomach in Japanese patientsGastric Cancer, 2013
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trialThe Lancet, 2010
- D2 Lymphadenectomy Alone or with Para-aortic Nodal Dissection for Gastric CancerNew England Journal of Medicine, 2008
- Chemotherapy for metastatic gastric cancer: past, present, and futureJournal of Gastroenterology, 2008
- S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trialThe Lancet Oncology, 2008
- Standard cancer patient population for age standardising survival ratiosEuropean Journal of Cancer, 2004
- S-1 in gastric cancer: a comprehensive reviewGastric Cancer, 2003